GP73 is a glucogenic hormone that contributes to SARS-CoV-2-induced hyperglycemia

Luming Wan  
Beijing Institute of Biotechnology  
https://orcid.org/0000-0002-0698-4077

Qi Gao  
Hotgen Biotech Co., Ltd. Beijing

Huilong Li  
Beijing Institute of Biotechnology

Huan Yang  
Beijing Institute of Biotechnology

Jing Gong  
Beijing Institute of Biotechnology

Yong-Qiang Deng  
Beijing Institute of Microbiology and Epidemiology  
https://orcid.org/0000-0002-2306-1039

Yuehua Ke  
Center for Disease Control and Prevention of PLA

Xiaopan Yang  
Beijing Institute of Biotechnology

Linfei Huang  
Beijing Institute of Biotechnology

Haotian Lin  
Beijing Institute of Biotechnology

Yanhong Zhang  
Beijing Institute of Biotechnology

Huapeng Wang  
Beijing Institute of Biotechnology

Changjun Wang  
Center for Disease Control and Prevention of PLA, Beijing, China

Xiaoli Yang  
Department of Clinical Laboratory, the Third Medical Centre, Chinese PLA General Hospital

Dongyu Li  
Beijing Institute of Biotechnology

Yumeng Peng  
Beijing Institute of Biotechnology, Academy of Military Medical Sciences (AMMS), Beijing, China

Qiulin Yan
Institute of Physical Science and Information Technology, Anhui University, Hefei

Xiaolin Wang  
Beijing Institute of Biotechnology

Changqing Lin  
Beijing Sungen Biomedical Technology Co. Ltd., Beijing, China

Fei Zheng  
Beijing Sungen Biomedical Technology Co. Ltd., Beijing, China

Lei Xu  
Beijing Sungen Biomedical Technology Co. Ltd., Beijing, China

Jingfei Li  
Department of Laboratory Medicine, Taian City Central Hospital Branch, Taian

Yinxin Xu  
Guangxi liver cancer Diagnosis and Treatment Engineering and Technology research center, Nanning, China

Zhiwei Sun  
Beijing Sungen Biomedical Technology Co. Ltd., Beijing, China

Feixiang Wu  
Beijing Institute of Biotechnology

Cheng-Feng Qin  
Beijing Institute of Microbiology and Epidemiology  https://orcid.org/0000-0002-0632-2807

Congwen Wei  
Beijing Institute of Biotechnology

Hui Zhong (✉ towall@yahoo.com)  
Beijing Institute of Biotechnology, Academy of Military Medical Sciences (AMMS), Beijing, China  
https://orcid.org/0000-0003-2128-9686

---

**Article**

**Keywords:** SARS-CoV-2, diabetes, COVID-19, glucogenic hormones, GP73

**Posted Date:** May 21st, 2021

**DOI:** https://doi.org/10.21203/rs.3.rs-537089/v1

**License:** This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License

**Version of Record:** A version of this preprint was published at Nature Metabolism on January 6th, 2022.  
See the published version at https://doi.org/10.1038/s42255-021-00508-2.
Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection induces new-onset diabetes and severe metabolic complications of pre-existing diabetes. The pathogenic mechanism underlying this is incompletely understood. Here, we provided evidence linking circulating GP73 with the exaggerated gluconeogenesis triggered by SARS-CoV-2 infection. We found that SARS-CoV-2 infection or glucotoxic conditions increased GP73 production and secretion. Secreted GP73 then trafficked to the liver and kidney to stimulate gluconeogenesis through the cAMP/PKA pathway. By using global phosphoproteomics, we found a drastic remodeling of the PKA kinase hub exerted by GP73. Notably, plasma GP73 levels were elevated and positively correlated with blood glucose in patients with COVID-19 and diabetes. Neutralization of circulating GP73 in serum of individuals infected with SARS-CoV-2 or with diabetes reduced excessive gluconeogenesis in cultured hepatocytes, and lowered blood glucose levels in animal models of diabetes. Ablation of GP73 from whole animals has a profound glucose-lowering effect secondary to reduced gluconeogenesis. Thus, GP73 is a key glucogenic hormone contributing to SARS-CoV-2-induced glucose abnormality.

Introduction

Under physiological circumstances, blood glucose levels are maintained within a narrow range to protect the body against hypoglycemia during fasting and excessive hyperglycemia following a high-carbohydrate meal. Glucose homeostasis is achieved primarily via hormonal modulation of glucose production by the liver and glucose uptake by skeletal muscle, heart muscle, and fat. Hepatic glucose production (HGP) involves a combination of glycogen breakdown (glycogenolysis) and de novo synthesis of glucose from noncarbohydrate precursors (gluconeogenesis). Gluconeogenesis is the main contributor to hepatic and renal glucose production during prolonged fasting states. The rate of gluconeogenic flux is controlled by the activities of key unidirectional enzymes, such as pyruvate carboxylase (PCX), phosphoenolpyruvate carboxykinase 1 (PCK1), fructose 1,6-bisphosphatase (FBP1), and glucose-6-phosphatase (G6Pase). The genes encoding these proteins are strongly controlled at the transcriptional level by key hormones including insulin, glucagon, and glucocorticoids. Excessive HGP not only contributes to exaggerated fasting and postprandial hyperglycemia in type 1 diabetes (T1D) and type 2 diabetes (T2D) patients, but also contributes to stress-, infection-, and inflammation-associated hyperglycemia.

From January 2020, the world has been facing an unprecedented outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Of note, SARS-CoV-2 infection can induce new-onset diabetes and severe metabolic complications in patients with pre-existing diabetes. Although impaired insulin secretion due to β-cell infection could contribute to the metabolic dysregulation observed in patients with COVID-19, the pathogenic mechanisms underlying new-onset T2D are largely unknown.
GP73 is a type II transmembrane Golgi protein located at the luminal surface of the Golgi apparatus, consisting of a short N-terminal cytoplasmic domain, a transmembrane domain, and a large C-terminal domain. GP73 cycles out of the cis-Golgi to endosomes for cleavage by the convertase furin, which results in its release into the extracellular space\textsuperscript{15,16}. Circulating GP73 is implicated in the regulation of cell-to-cell communication triggered by the unfolded protein response\textsuperscript{17}. The present study provides evidence that GP73 is a fasting-induced hormone that promotes hepatic and renal glucose production in endocrine and autocrine manners. Notably, SARS-CoV-2 infection and hyperglycemia greatly increased the secretion of GP73. Therefore, targeting GP73 might be a potential therapeutic strategy for patients with SARS-CoV-2 infection and diabetes who present alterations in the levels of this hormone.

**Results**

**SARS-CoV-2 infection promotes GP73 production and secretion**

The fact that hepatocyte GP73 expression is upregulated in patients with viral and nonviral liver disease suggests that this protein is triggered during hepatocyte injury\textsuperscript{18}. The liver damage caused by SARS-CoV-2 infection prompted us to investigate whether infection with this virus altered GP73 expression\textsuperscript{19}. Notably, SARS-CoV-2-infected patients had approximately 2-fold higher circulating GP73 levels than the reference population (P < 0.0001; Table 1 and Fig. 1a). When disease status was classified into mild, moderate, and severe, the serum GP73 concentration was significantly higher in patients with severe or moderate disease than patients with moderate or mild disease (Table 2 and Fig. 1b).

To assess whether cultured hepatocytes are capable of generating and secreting GP73, human hepatocyte Huh-7 cells were infected with SARS-CoV-2, and GP73 secretion was examined over time during infection. Successful infection was confirmed by the observation of increasing extracellular viral RNA levels over the course of the infection period (Fig. 1c-d). Interestingly, cultured hepatocytes exposed to SARS-CoV-2 exhibited a robust time- and dose-dependent increase in GP73 secretion (Fig. 1e-f). Intracellular GP73 protein expression was also increased in SARS-CoV-2-infected cells (Fig. 1g). In particular, we did not observe any detectable GP73 accumulation in Huh-7 cells lacking GP73 (GP73 KO-1) following SARS-CoV-2 infection (Fig. 1h-i). Together, these results demonstrate that SARS-CoV-2 infection promotes the cellular secretion of GP73.

**Increase In Circulating GP73 Elevates Fasting Blood Glucose**

To understand the acute response to elevated circulating GP73 levels, we expressed and purified the mouse GP73 c-terminal fragment (52–401; rmGP73) with His-Tag (Extended Data Fig. 1a). A mouse GP73 sandwich ELISA was developed and specificity was confirmed using plasma from WT and GP73 KO mice (Extended Data Fig. 1b-d). Administration of a single dose of 0.1 mg/kg rmGP73 led to an approximately 2-fold increase in plasma GP73 levels compared to control mice, with a half-life of approximately 30 min (Extended Data Fig. 1e-f). We then experimentally elevated plasma GP73 levels via the intravenous (i.v.) injection of 0.1 mg/kg rmGP73 into mice subjected to a preceding 12-h fast. In this setting, rmGP73 induced an immediate spike in blood glucose levels (Fig. 2a). A GP73-specific antibody
completely blocked the glucose-stimulating effect of recombinant GP73 (Fig. 2b). It should be noted that compensatory hyperinsulinemia was not sufficient to normalize blood glucose levels by 48 h post-injection, as mice receiving rmGP73 still displayed higher blood glucose levels (Fig. 2c-d). We then injected rmGP73 daily for three days. Repeated GP73 injection produced a sharp rise in blood glucose levels (Fig. 2e).

Hyperglycemia is caused either by impaired glucose clearance and/or excess glucose production through glycogenolysis or gluconeogenesis. To determine which of these processes caused GP73-induced hyperglycemia, we performed an insulin tolerance test (ITT). There were no significant differences in mice challenged with rmGP73 (Fig. 2f). However, when we assessed insulin resistance with the glucose tolerance test (GTT), we observed that rmGP73 severely impaired glucose clearance (Fig. 2g). The pyruvate tolerance test (PTT) indicated that the conversion of pyruvate to glucose was greatly enhanced after GP73 challenge in overnight-fasted, glycogen-depleted mice (Fig. 2h) and that this effect was completely blocked by anti-GP73 treatment (Fig. 2i). GP73 elevation also stimulated alanine-driven gluconeogenesis in a glycogen-depleted state (Fig. 2j). Notably, no significant difference was found in hepatic glycogen content between the rmGP73- and PBS-injected mice (Fig. 2k), suggesting that glycogenolysis was not affected by GP73. In particular, neutralizing circulating GP73 with GP73 mAb in fasting animals attenuated the ability of mice to maintain normoglycemia (Fig. 2l). We thus hypothesized that fasting induced GP73 may mainly function to maintain normoglycemia by potentiating endogenous glucose production.

**Circulating GP73 traffics to liver and kidney to stimulates gluconeogenesis**

To examine the primary target of circulating GP73, rmGP73 labeled with Cy-7 (rmGP73-Cy7) was injected into mice, and an in vitro imaging system (IVIS) was used to identify sites of accumulation. An equivalent amount of free Cy7 was used as a control. In contrast to free Cy7, rmGP73-Cy7 trafficked primarily to the liver and kidney (Extended Data Fig. 2a) and exhibited higher accumulation in these two tissues 30 min after injection (Fig. 3a and Extended Data Fig. 2b). In addition, the fluorescence signal in the liver 19 h post-administration was 20% of the signal at 1 h (Extended Data Fig. 2c-d). Moreover, GP73 bound to the surface of hepatocytes and renal cells in a dose-dependent and saturable manner (Fig. 3b and Extended Data Fig. 2e-f).

We then directly assessed the effect of GP73 on glucose production in isolated primary mouse hepatocytes (PMHs). Treatment of PMHs isolated from overnight-fasted mice with rmGP73 promoted HGP in a dose- and time-dependent manner (Fig. 3c and Extended Data Fig. 3a). A similar result was observed in rat primary hepatocytes treated with recombinant rat GP73 (rrGP73; Extended Data Fig. 3b). In particular, GP73-specific antibody blocked GP73-mediated hepatocyte glucose release (Extended Data Fig. 3c). A competitive antagonist of cyclic AMP (cAMP) binding to PKA, cAMPS-Rp, blocked GP73-mediated hepatocyte glucose release in a similar manner as glucagon (Extended Data Fig. 3d). The addition of rmGP73 also led to increased expression of key gluconeogenic enzymes, increased intracellular cAMP levels and PKA kinase activity (Fig. 3d and Extended Data Fig. 3e-f). Phosphorylation
of the PKA-C-α subunit and PKA substrate levels in hepatocytes and renal cells were also significantly increased by GP73 (Fig. 3e-f). Meanwhile, increased levels of cAMP response element-binding (CREB) phosphorylation and G6pc expression were observed in liver tissues from mice exposed to a single dose of rmGP73 (Extended Data Fig. 3g-h). GP73 treatment also tended to decrease insulin-stimulated phosphorylation of AKT at Ser473 in PMHs, HepG2 cells, and mouse myotube L6 cells (Fig. 3g). Thus, GP73 regulates hepatocyte glucose production and peripheral insulin sensitivity.

GP73 induces a drastic remodeling of the PKA kinase hub

To determine the full extent of the hepatic signaling effect of circulating GP73 at the cellular level in the absence of systemic factors that may exert compensatory effects, we performed global phosphoproteomics analysis in PMHs treated with PBS, rmGP73, or glucagon in vitro. A total of 183 and 229 phosphosites were identified in the GP73-treated and glucagon-treated samples, respectively (Fig. 4a). Of the top 30 phosphosites that were highly upregulated by GP73, over 75% were also affected by glucagon (Fig. 4b), indicating that these two proteins have overlapping functions at the signaling level. Among the potentially functional phosphosites regulated by GP73, Ser1588 of inositol triphosphate receptor-1 (Itpr1, also known as InsP3R-I) attracted our attention (Fig. 4c). This protein is a target of PKA and plays a crucial role in glucagon-stimulated hepatic gluconeogenesis. Other proteins significantly regulated by GP73 that are known to be involved in gluconeogenesis signaling included PHKA2S729, GNMTY221, SLC16A1S491, MLXS45, BADS155, CTNNBS552, GPX1S7, CYP2E1S129, and HCFC1S1516 (Fig. 4c).

To investigate the mechanisms responsible for the phosphoproteome changes, kinase substrate motifs were extracted, and a clear shift towards PKA kinase activation following GP73 or glucagon stimulation was identified (Fig. 4d). Other substrate motifs of key kinases previously implicated in the regulation of gluconeogenesis and insulin resistance, including GSK3B, PRKG1, PTK2B, and CaMK2A, were also dysregulated, which further explains the ability of GP73 to affect glucose production and insulin sensitivity (Fig. 4e and Extended Data Fig. 4a). Additional enriched kinase motifs following GP73 stimulation included mitogen-activated kinase (MAPK) 3/8/9/10/13/14 and cyclin-dependent kinase (CDK)1/2 (Fig. 4e). Global kinase enrichment analysis following GP73 stimulation revealed that GP73 induced a drastic remodeling of PKA hubs in a similar manner as glucagon (Extended Data Fig. 5a-b). Pathway analysis of the phosphosites regulated by GP73 revealed pathways related to cell-cell adhesion, cell endocytosis, mRNA processing, gene transcription, and cell cycle regulation (Extended Data Fig. 4b). At the signaling level, the mTOR pathway, FoxO pathway, and insulin pathway were positively enriched in GP73-treated hepatocytes (Fig. 4f). Therefore, GP73 induces a drastic remodeling of the PKA kinase hub and multiple signaling pathways.

GP73 is induced from multiple tissues upon fasting and under glucotoxic conditions

Given the glucogenic roles of GP73 in glucose homeostasis, we hypothesized that GP73 levels were regulated in response to fasting signals. Indeed, fasting in humans and mice increased plasma GP73 levels (Fig. 5a-b). Since intracellular GP73 overexpression led to the release of GP73 into the extracellular
space (Extended Data Fig. 6a-b), we examined and compared GP73 expression in metabolically important organs isolated from ad libitum-fed and fasted mice to delineate the source of GP73 under fasting conditions. After 24 h of fasting, we found a strong upregulation of GP73 mRNA expression in the heart, liver, kidney, white adipose tissue (WAT), and pancreas (Extended Data Fig. 6c). The upregulation of GP73 in the liver persisted for 48 h of fasting then dropped to levels lower than the fed and refed states, while the upregulated GP73 in the kidney was progressively elevated with prolonged fasting times compared to its levels in the fed and refed states (Fig. 5c). Consistent with this finding, the intensity of GP73 immunofluorescence staining in liver, WAT, and pancreatic tissues was significantly increased upon 24 h of fasting (Fig. 5d and Extended Data Fig. 6d). GP73 secretion from cultured HepG2 cells was also promoted in response to the fasting-related signal forskolin (Extended Data Fig. 6e). To further identify the pancreatic cell type that produced GP73 in response to fasting, we examined GP73 staining in islets isolated from fasted mice using triple immunofluorescence staining for glucagon (a marker for α cells), insulin (a marker for β cells) and GP73. Specifically, GP73 primarily colocalized with β cells (Extended Data Fig. 6f-g). Thus, GP73 secretion is induced from multiple cell types upon fasting.

Since excessive gluconeogenesis directly predisposes the host to abnormal glucose metabolism, we then examined the clinical association between GP73 expression and blood glucose levels in patients with COVID-19. Indeed, blood glucose levels in COVID-19 patients were higher than those in the reference population and were particularly higher in patients with severe disease (Extended Data Fig. 6h-i). Strikingly, the plasma GP73 levels in COVID-19 patients were positively correlated with blood glucose levels (Fig. 5e). Moreover, the plasma concentrations of GP73 were higher in patients with diabetics and correlated with average blood glucose levels (glycated A1c, HbA1c; Fig. 5f-g). We then wanted to assess whether hyperglycemia is a potential driving force in the upregulation of GP73 expression. A strong upregulation of GP73 mRNA expression in WAT and liver was identified in mice injected with high glucose and in HFD plus streptozotocin (STZ)-induced T2D mice (Fig. 5h-i). The upregulation in liver tissue in T2D mice was notably striking, indicating that the liver is a major source of plasma GP73 under glucotoxicity conditions. Therefore, the pathophysiological relevance of GP73 to hyperglycemia associated with SARS-CoV-2 infection and diabetes was established.

**GP73 blockade reduces excessive gluconeogenesis associated with SARS-CoV-2 infection and diabetes**

After confirming the role of GP73 as a glucogenic hormone, we hypothesized that SARS-CoV-2-induced hyperglycemia might result from excessive gluconeogenesis triggered by the upregulation of GP73 expression. Indeed, the stimulatory effects of SARS-CoV-2 on the induction of glucogenic gene expression and hepatocyte glucose production were markedly reduced by GP73 antibody treatment (Fig. 6a-b), similar to the effect of GP73 depletion (Fig. 6c and Extended Data Fig. 7a). Meanwhile, PKA activation by SARS-CoV-2 infection was also significantly blocked by a GP73-specific antibody (Fig. 6d). To further investigate whether the changes in serum GP73 were closely associated with gluconeogenesis levels, we obtained serum from COVID-19 patients with GP73 levels higher than 60 ng/ml and age-matched healthy individuals with GP73 levels lower than 20 ng/ml and added the samples to culture medium. Glucogenic gene expression and PKA enzymatic activity were more strongly induced in cells exposed to serum from
COVID-19 patients than in cells exposed to serum from healthy controls, and these effects were significantly blocked by anti-GP73 antibody (Fig. 6d-e). Therefore, circulating GP73 was necessary for SARS-CoV-2-induced gluconeogenesis enhancement (Extended Data Fig. 7b).

Since targeting GP73 is a therapeutic strategy for treating patients with this altered hormone level during insulin resistance, the effect of the GP73 antibody on excessive gluconeogenesis associated with diabetes was then explored. As expected, PKA enzymatic activity was more strongly induced in hepatocytes exposed to serum from diabetic patients than serum from healthy controls (Extended Data Fig. 8a). Specifically, treatment with an anti-GP73 antibody blocked PKA activation induced by serum from diabetic patients (Fig. 6d). To further confirm this therapeutic effect, we used \textit{db/db} T2D mice, which exhibit severe fasting hyperglycemia (Fig. 6f), increased hepatic and renal GP73 expression, and upregulated glucogenic gene expression (Extended Data Fig. 8b-d). Fasting blood glucose levels were significantly decreased in the GP73 antibody-treated mice compared to the IgG-treated mice 6 h after administration (Fig. 6g). A similar result was obtained in the HFD + STZ-induced T2D mouse model (Fig. 6h).

To validate immunologic sequestration as a legitimate loss-of function strategy, we deleted GP73 from whole body by CRISPR-Cas9 strategy. In adult male mice, GP73 heterozygous (Hz) and homozygous (KO) showed lower glucose levels in the fed and fasted state when compared with WT littermate controls (Extended Data Fig. 9a-b). No significantly different blood glucose levels were identified in adult female mice (Extended Data Fig. 9c-d). Therefore, male mice were used unless referred. Lower fasting insulin levels and similar glucagon levels in adult GP73 KO mice were observed (Extended Data Fig. 9e-f). Decreased hepatic glucose production along with reduced fasting-induced gluconeogenic genes expression in the liver and kidney were further proved in GP73 KO mice (Extended Data Fig. 9g-i). Of note, rmGP73 addition in primary hepatocytes isolated from overnight-fasted GP73 KO mice was sufficient to completely rescue the HGP deficiency displayed by these cells (Extended Data Fig. 9j). All these results indicate that GP73 blockade has a profound glucose-lowering effect that is primarily due to reduced gluconeogenesis.

**Discussion**

Precise regulation of gluconeogenesis required for physiological adaptation to fasting and starvation occurs at multiple levels\textsuperscript{6,20}. In response to stimulation by external factors, the circulating blood levels of insulin, glucagon and glucocorticoids change, leading to subsequent changes in glucogenic pathways and glucose production\textsuperscript{21}. Here, we provide evidence linking circulating GP73 to gluconeogenesis. Consistent with the fact that hepatic glucose release is necessary during fasting, the circulating concentration of GP73 rises during fasting. GP73 blockade in fasted mice failed to maintain normal blood glucose levels during fasting period. Experimentally changing the circulating GP73 concentration via direct recombinant protein injection, genetic depletion or immunologic sequestration leads to corresponding changes in fasting plasma glucose. Mechanistically, secreted GP73 primarily targeted the liver and kidney to promote gluconeogenesis via activation of PKA signaling in endocrine and autocrine...
manner. By establishing a pathological role for elevated serum GP73 in excessive gluconeogenesis associated with SARS-COV-2 infection and diabetes, we hypothesize that the hyperglycemia during SARS-COV-2 infection or lifestyle-related diabetes might partly converge on the glucogenic property of GP73 (Extended Data Fig. 10).

We assessed the direct actions of GP73 in the regulation of glucose production in primary hepatocytes in the absence of other counterregulatory hormones. GP73 was sufficient to cause cAMP accumulation, stimulate the enzymatic activity of PKA, increase the phosphorylation of CREB, and enhance the transcriptional expression of \( Pcx \), \( Pck1 \), and \( G6pc \). These results suggest that GP73 stimulates gluconeogenesis via the activation of PKA signaling through transcriptional regulation. In support of this, we observed a drastic remodeling of the PKA hub following GP73 challenge using phosphoproteomics. Likewise, phosphosites that were upregulated by glucagon were also significantly enriched with substrate motifs for PKA, indicating that glucagon and GP73 have overlapping functions at the signaling level. Among the unique kinases affected by GP73, protein kinase C\(\beta\) and p38 MAPK were identified, and both contribute to hepatic steatosis and insulin resistance. Identification of the cell-surface receptor through which GP73 exerts its effects may provide more mechanistic information. Epidemiological and experimental data indicate that SARS-CoV-2 infection is involved in the development of diabetes. The mechanisms underlying this phenomenon are complex and may include the promotion of inflammation, structural lung damage, and systemic effects. The present study reported that SARS-CoV-2 infection was associated with insulin resistance via pathways involved in endogenous glucose production. We demonstrated that enhanced gluconeogenic metabolism following SARS-CoV-2 infection was primarily dependent on GP73. Targeting GP73 may be a therapeutic strategy for the treatment of patients with altered levels of this hormone during SARS-CoV-2 infection.

We established a positive correlation between serum GP73 and blood glucose levels in patients with SARS-CoV-2 infection, and observed increased GP73 expression under glucotoxic conditions. These results suggest that the persistent elevation of GP73 levels in patients with late-stage COVID-19 may be driven primarily by suboptimal blood glucose control rather than the infection per se. The exact drivers for the stimulation of GP73 expression in physiological and pathological states require further investigation. However, we hypothesized that the alterations in glucose metabolism following sudden onset of COVID-19 will persist even after the infection resolves. In fact, it has been observed that hyperglycemia persists for 3 years after recovery from SARS\(^{22}\). Apart from the role of GP73 in promoting cell proliferation, tumor development, and metastasis\(^{23}\), GP73 also represses the host innate immune response to promote RNA virus replication\(^{24}\). Therefore, long-term follow-up of infected patients is a priority.

In summary, our results provide convincing evidence that SARS-CoV-2 infection induces GP73 expression, which results in an exaggerated gluconeogenic response and may directly predispose the host to abnormal glucose metabolism. Our findings support the exciting possibility that neutralizing plasma GP73 may be an efficient approach for the treatment of infection- and lifestyle-related diabetes.

**Methods**
Reagents

Sodium L-lactate (71718), sodium pyruvate (792500), streptozotocin (STZ, S0103) and aprotinin (A6106) were purchased from Sigma-Aldrich (Missouri, USA). Insulin (2018283062) was purchased from Novo Nordisk (Bagsværd, Denmark). Glucagon (HY-P0082) and FSK (HY-15371) were purchased from MedChemExpress (New Jersey, USA). Glucose (20171108) was purchased from Sinopharm Chemical Reagent (Beijing, China). A blood glucose meter (06656919032) and test strips (1072332990) were purchased from Roche (Basel, Switzerland). Sulfo-Cyanine7 NHS ester (Cy7, GY1058) was purchased from Goyo Biotechnology (NanJing, China). Dulbecco’s modified Eagle medium (DMEM, high-glucose, D5796), protease inhibitor cocktail I (20-201) and a dipeptidyl peptidase-4 (DPP4) inhibitor (DPP4-010) were purchased from Millipore (Massachusetts, USA). Low-glucose DMEM (31600-500), glucose-free DMEM (90113-500) and L-alanine (A8210) were purchased from Solarbio (Beijing, China). Fetal bovine serum (FBS, A3160901) was purchased from Gibco (New York, USA). Lipofectamine™ 2000 (11668-027) was purchased from Invitrogen (Massachusetts, USA). Chow (HD1001) and a HFD (HD001) were purchased from BiotechHD (Beijing, China). cAMPS-Rp triethylammonium salt (151837-09-1) was purchased from Tocris Bioscience (Bristol, England). Collagenase IV (2091) was purchased from BioFroxx (Einhausen, Deutschland). PerfectStart™ Green qPCR SuperMix (AQ601) and TransScript® One-Step gDNA Removal and cDNA Synthesis SuperMix (AT311) were purchased from TransGen Biotech (Beijing, China). NucleoZOL (740404) was purchased from MACHEREY-NAGEL (MN, Düren, Deutschland). A mouse insulin ELISA kit (PI602) and BCA protein concentration determination kit (P0012) were purchased from Beyotime (Shanghai, China). A mouse glycate plasma protein kit (80420) was purchased from Crystal Chem (Washington, USA). Mouse aspartate transaminase (AST, 200218), alanine transaminase (ALT, 191230), triglyceride (TG, 200224) and cholesterol (CHO, 200224) biochemical test kits were purchased from Ruierda Biological Technology (Beijing, China). A cAMP assay kit (ab133051) and PKA Kinase Activity Kit (ab139435) were purchased from Abcam (Illinois, USA). An Amplex™ Red Glucose/Glucose Oxidase Assay Kit (A22189) was purchased from Invitrogen (Massachusetts, USA).

Antibodies

Anti-α-tubulin (T6074, 1:5,000 dilution) and anti-Flag (A8592, 1:5,000 dilution) antibodies were purchased from Sigma-Aldrich (Missouri, USA). Anti-glucagon (ab92517, 1:2500 dilution), anti-insulin (ab6995, 1:200 dilution), anti-CREB-phospho S133 (ab32096, 1:1000 dilution), and anti-CREB (ab32515, 1:1000 dilution) antibodies were purchased from Abcam (Illinois, USA). An anti-GP73 antibody (F-12, sc-393372, 1:200 dilution) was purchased from Santa Cruz (Texas, USA). An anti-His antibody (KM8001, 1:1000 dilution) was purchased from Taihua Lekang Biotechnology (Beijing, China). Anti-phospho-Akt (Thr308, 13038, 1:1000 dilution), anti-Akt (9272, 1:1000 dilution), anti-phospho-PKA-C-α (Thr197, 5661, 1:1000 dilution), anti-phospho-PKA substrate (RRXpS/T, 9624, 1:1000 dilution), and anti-PKA-C-α (5842, 1:1000 dilution) antibodies were purchased from Cell Signaling Technology (Danvers, USA). Anti-rabbit HRP-IgG (ZB-2301, 1:5000 dilution) and anti-mouse HRP-IgG (ZB-2305, 1:5000 dilution) secondary antibodies were purchased from ZSGB-BIO (Beijing, China). An anti-GP73 monoclonal antibody (mAb) for the blocking
experiment was custom made. Isotype-matched IgG (A7028) was purchased from Beyotime (Shanghai, China).

**Plasmids and cell culture**

Mammalian expression vectors encoding Flag-tagged human, mouse and rat GP73 were constructed by inserting the corresponding PCR-amplified fragments into pcDNA3 (Invitrogen, Massachusetts, USA). The HepG2 (CRL-10741), Vero E6 (CRL-1568), HK-2 (CRL-2190), 293T (CRL-3216) and L6 (CRL-1658) cell lines were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). The Huh-7 (0403) cell line was obtained from the Japanese Collection of Research Bioresources. All cell lines were tested for mycoplasma contamination and were incubated in DMEM at 37°C in a humidified atmosphere with 5% CO₂. Lipofectamine™ 2000 was used for transfection following the manufacturer's protocol.

To knock out human GP73 in Huh-7 cells, two small guide RNAs (sgRNAs) targeting GP73 were designed and inserted into the LentiCrispr v2 vector to construct transfer plasmids. 293T cells were transfected with pMD2. G, psPAX2 and the corresponding transfer plasmid to produce lentivirus. A total of 10⁸ Huh-7 cells were infected with lentivirus at a multiplicity of infection (MOI) of 2.0 and selected with 4 μg/mL puromycin for two weeks to ensure proper selection.

The following sgRNA sequences were used:

sgRNA-1: 5’-CACCGCACACACAGAGGTGCCACAA-3’
sgRNA-2: 5’-CACCGACCAGTTAAAGACCCTGCAG-3’
control- 5’-CACCGCGCTTCCGCGGCCCGTTCAA-3’.

PMHs were isolated and purified using a modified two-step collagenase perfusion method. Cells were resuspended in low-glucose DMEM containing 5% FBS and seeded on 15-cm dishes at 80% confluence. Five hours later, the cells were washed and cultured in serum-free medium overnight. For gluconeogenesis-related assays, the medium was replaced with glucose- and phenol-free DMEM the next day in the presence of 10 mM pyruvate sodium and 10 mM sodium lactate, and the cells were treated with the indicated concentrations of rmGP73 or rrGP73, 200 mM cAMPS-Rp, or 2 μM glucagon. Then, 64 nM GP73 was used for 10 min for the cAMP and PKA assays and for 1 h for phosphoproteomics. The results were normalized to the protein content.

**Sample acquisition from COVID-19 patients**

The Ethics Committee of Huoshenshan Hospital approved the study (HSSLL036). Given the urgency of the COVID-19 pandemic, the need for informed consent forms was waived by the ethics boards of the hospitals. Basic information and serum biochemical test results were collected from 136 COVID-19 patients at Huoshenshan Hospital (Wuhan, Hubei province, People's Republic of China) from January 11 to March 11, 2020. Diagnosis was based on chest computed tomography (CT) manifestations and/or
reverse transcription-polymerase chain reaction (RT-PCR) according to the criteria of the New Coronavirus Pneumonia Prevention and Control Program (5th edition) published by the National Health Commission of China. According to these criteria, COVID-19 patients were classified into mild, moderate, and severe COVID-19 subgroups. Data were excluded if the subject was younger than 18 years or older than 75 years, had incomplete medical records, acute lethal organ injury (e.g., acute myocardial infarction, acute coronary syndrome, acute pulmonary embolism, or acute stroke), or decompensated or end-stage chronic organ dysfunction (e.g., decompensated cirrhosis, decompensated chronic renal insufficiency, or severe congestive heart failure), were pregnant or had malignancy (Table 1). Human blood samples were collected from the COVID-19 patients analyzed in this study before intervention. Fifty patients were classified as having mild COVID-19, 65 patients had moderate COVID-19, and 21 patients had severe COVID-19 (Table 2).

**Sample acquisition from healthy and diabetic patients**

Human blood samples from the healthy and diabetic patients used in this study were obtained from individuals admitted to the Third Medical Center of the Chinese PLA General Hospital. The detailed characteristics of the recruited subjects are described in Table 3. All individuals in this study provided a signed statement of consent. The Committee for Ethics in Human Studies from the Third Medical Center of the Chinese PLA General Hospital approved this study (KY2021-009).

**Infection with authentic SARS-CoV-2**

The SARS-CoV-2 strain (2019-nCoV BetaCoV/Beijing/AMMS01/2020) used in the present study was isolated from the lung lavage fluid of an infected patient and preserved at the State Key Laboratory of Pathogen and Biosecurity at Beijing Institute of Microbiology and Epidemiology. SARS-CoV-2 infections were performed in the BSL-3 Laboratory of the Beijing Institute of Microbiology and Epidemiology. The infectious virus titer was determined as plaque-forming units in Vero E6 cells and was used to calculate the MOI. Cells were infected with SARS-CoV-2 at the indicated MOIs for the indicated times in glucose-free medium for the production assay. The results were normalized to the protein content. Cells were infected with SARS-CoV-2 at the indicated MOIs for the indicated time, and the supernatant was harvested for the GP73 assay and viral load assay. Viral RNA was extracted from the supernatants using the QIAamp Viral RNA Mini Kit (52906, Qiagen) according to the manufacturer's instructions. Viral RNA was analyzed using qRT-PCR and a One-Step PrimeScript RT-PCR Kit (RR064B, TaKaRa) using SARS-CoV-2-specific primers in an Applied Biosystems 7500 Real-time PCR System. The following sequences of the SARS-CoV-2 probes were used:

SARS-CoV-2 open reading frame 1b (ORF1b):

Forward: 5'- CCCTGTGGGTTTTACACTTAA-3’

Reverse: 5'- ACGATTGTGCATCAGCTGA-3’.

Probe: 5’-FAM- CCGTCTGCGGTATGTGGAAAGGTTATGG-BHQ 1-3’. 
SARS-CoV-2 nucleocapsid (N):

Forward: 5'- GGGAACCTCTCCTGCTAGAAT-3'
Reverse: 5'- CAGACATTGGCTCTCAAGCTG-3'.
Probe: 5'-FAM- TTGCTGCTGCTTGACAGATT-BHQ 1-3'.

The number of copies per microliter (μl) was determined using a synthetic RNA fragment to amplify the target region.

**Recombinant GP73 protein purification**

Human, mouse, and rat GP73 cDNAs, each with a six-amino-acid His tag on the N-terminus, were cloned into the pCDNA3.1 vector. Ni-NTA His-Bind column-bound His-GP73 protein from 293T cells transfected with the above plasmids was further purified using size-exclusion columns and polymyxin B-based endotoxin-depletion columns after extensive washing. The final His-GP73 proteins used in all recombinant protein experiments were >90% pure (endotoxin<=2 EU/ml) and stored at -80°C.

**Animals, intervention and monitoring**

Male C57BL/6N WT mice (8 to 10 weeks old) were purchased from SPF Biotechnology (Beijing, China). GP73 KO mice (T20200316-18[D25]) were generated by Southern Model Biotechnology (Shanghai, China). Male C57 BLKS/J db/db and BKS control mice (8 weeks, 36-40 g) were purchased from GemPharma Tech Co. Ltd. (Jiangsu, China). All mice were group-housed conventionally on a 12-h light/dark cycle for 3 days before any experiments. All animal experiments were performed at the AMMS Animal Center (Beijing, China) and were approved by the Institutional Animal Care and Use Committee.

For single injections, mice were injected i.v. with 0.1 mg/kg recombinant His-tagged GP73, and plasma was collected at the indicated times via tail bleeding for insulin and glucose level measurements. The ITT, GTT, PTT, and ATT were performed using standard procedures. A 0.75 U/kg insulin bolus was used for the ITT, a 1.5 g/kg glucose bolus was used for the GTT, a 1.5 g/kg pyruvate bolus was used for the PTT, and a 0.6 g/kg alanine bolus was used for the ATT. For immunological sequestration experiments, mice were injected i.v. with 15 mg/kg custom-made anti-GP73 mouse mAb or an equivalent dose of IgG (30 mg/kg).

To establish an HFD-induced STZ model, mice were maintained on a regular chow diet or fed an HFD for 1 month beginning at 4 weeks of age. STZ (40 mg/kg) in citric acid buffer (0.1 mol/L, pH 4.2) was administered to male C57BL/6N mice via intraperitoneal injection, and the same dose of STZ was injected 24 h later. After STZ injection, the mice were fed an HFD for another month. Fasting blood glucose and random blood glucose levels were measured weekly. The mice were confirmed to have diabetes if their fasting blood glucose levels were over 199.8 mg/dL or their random blood glucose levels were over 300.6 mg/dL. For all experiments, mice were randomly assigned to different groups to ensure an unbiased distribution.
Glucose measurement

All blood samples were collected from the tail, and glucose levels were measured using the glucose oxidase method and an automated blood glucose reader (ACCU-CHEK, Roche). For the measurement of fasting blood glucose levels, normal mice were fasted for 6 or 12 h, as indicated. Random blood glucose levels were measured at 9:00 a.m. If the glucose level was greater than 630 mg/dL (upper detection limit of the glucometer), a value of 630 mg/dL was recorded. Blood glucose levels were determined.

Assays of plasma hormone levels

Blood samples for hormone detection were collected from the tail or orbital vein. A DPP4 inhibitor (1:100 dilution), aprotinin (1:100 dilution) and protease inhibitor cocktail I (50000 KIU/mL, 1:100 dilution) were added to each blood sample. Plasma insulin levels were measured using ELISA.

Immunofluorescence staining

Tissues were fixed with 10% (v/v) neutral-buffered formalin at 4°C overnight and embedded in paraffin, and 5-μm-thick sections were prepared. For immunofluorescence, the sections were heated in an autoclave in citrate buffer (12 mmol/L, pH 6.0), preincubated in permeabilization/blocking buffer (0.1 mmol/L PBS, pH 7.3, 0.5% Triton) and blocked for 30 min with 10% (v/v) goat serum (Zhongshan Biotechnology, Beijing, China). The sections were subsequently incubated with primary antibodies at 4°C overnight and secondary antibodies for 1 h at room temperature, washed and stained with DAPI (1 μg/mL). Images were captured under a confocal fluorescence microscope (Zeiss LSM710, Carl Zeiss Microscopy GmbH, Jena, Germany) or an automatic digital slide scanner (Pannoramic MIDI, 3D HISTECH, Budapest, Hungary).

Phosphoproteomics

PMHs were suspended in low-glucose DMEM containing 5% FBS and seeded in 15-cm dishes at 80% confluence. The cells were washed and cultured in serum-free medium overnight 5 h later. The medium was replaced with glucose- and phenol-free DMEM supplemented with 10 mM pyruvate sodium and 10 mM sodium lactate the next day, and the cells were incubated for 1 h with PBS, rmGP73 (64 nM), or glucagon (2 μM). For cell lysate collection, the cells were washed twice with cold PBS and scraped with cold RIPA lysis buffer supplemented with protease and phosphatase inhibitors. Phosphoproteomics was performed by Oebiotech Company. Briefly, the samples were subjected to enzyme digestion and iTRAQ labeling, and the phosphopeptides were enriched and analyzed using LC-MS/MS. The raw data of this study have been deposited in the IProX database with the following accession number: PXD025381. For kinase enrichment, the Literature Based Kinase-Substrate Library with Phosphosites on the Kinase Enrichment Analysis 2 (KEA2) website was searched. The network was represented using Cytoscape ver 3.6.2 (https://cytoscape.org/). Protein-protein interactions were retrieved from STRING App (v1.51) (https://string-db.org/). Only interactions with high confidence (interaction score >0.7) from databases and experiences were kept. For KEGG and GO enrichment analysis, DAVID Bioinformatics Resources 6.8
(https://david.ncifcrf.gov/home.jsp) was used. For specific kinase substrate motif analysis, MoMo Modification Motifs 5.3.3 (http://meme-suite.org/tools/momo) was used.

**In vivo imaging system (IVIS)**

GP73 was labeled with Cy7 via the addition of the dye according to the manufacturer's instructions at a pH of 8.0 and incubation of the mixture for 4 h on ice. The labeled GP73 was returned to a pH of 7.0, and the free dye was removed via overnight dialysis in PBS. The labeled GP73 was added to a Sephadex G50 size exclusion column equilibrated with PBS. Fractions of 500 µL were collected, the protein concentration was analyzed using a standard BCA protein assay kit, and fluorescence corresponding to excitation/emission of 745/800 nm was assessed.

After i.v. injections with free Cy7 and GP73-Cy7, mice were scanned using an IVIS (PerkinElmer) at the indicated time points to assess fluorescence. After whole-body imaging, the mice were sacrificed, and the major organs were imaged to assess fluorescence under the same settings as the in vivo imaging. The data were analyzed and exported using built-in Living Image Software (Version 4.5.5, PerkinElmer).

**Quantitative real-time PCR (qRT-PCR)**

Total mRNA was extracted from cells or various mouse tissues using NucleoZOL. cDNA was prepared from total mRNA using TransScript® One-Step gDNA Removal and cDNA Synthesis SuperMix, and the relative levels of individual mRNAs were calculated after normalization to the GAPDH mRNA level in the corresponding sample as previously described. The primer sequences are presented in Table 4.

**Sandwich ELISA and Western blot analysis**

For endogenous GP73 sandwich ELISA, two custom-made rat monoclonal anti-GP73 antibodies were used as the capture antibody and the detection antibody. Briefly, the plate was coated with an unlabeled capture antibody, and serially diluted standards and samples were added to the plate. After three washes, HRP-linked detection antibody was added to generate a colorimetric signal at 450 nm. For His-tagged GP73 sandwich ELISA, the same procedure was used, except a goat anti-His polyclonal antibody (Abcam) was used as the detection antibody. Increasing amounts of recombinant His-tagged GP73 were used to generate a standard curve for both assays.

For immunoblotting, cells were lysed in NP40 cell lysis buffer with fresh protease inhibitors. Whole-cell lysates were separated using SDS-PAGE after centrifugation and transferred to PVDF membranes for immunoblot analyses using the indicated primary antibodies.

**Statistical analysis**

The present study used GraphPad Prism 8.0 for statistical calculations and data plotting. Differences between two independent samples were evaluated using two-tailed Student's t-tests or the Mann-Whitney test, as appropriate. Differences between multiple samples were analyzed using one-way ANOVA or two-
way ANOVA followed by Bonferroni's post hoc test, as appropriate. Correlations were analyzed using Spearman's non-parametric test. All tests were two-tailed unless otherwise indicated. We considered a P value $\leq 0.05$ as statistically significant. Significance values were set as follows: ns (not significant), $P > 0.05$; *, $P < 0.05$; **, $P < 0.01$; and ***, $P < 0.001$.

**Declarations**

**Data Availability Statement**

The data that support the findings of this study are available from the corresponding author upon reasonable request.

**Acknowledgements**

We thank the National Key Research and Development Programme of China (grant no. 2018YFA0900800) and National Natural Science Foundation of China (grant nos. 31872715 32070755 81773205 and 82070595) for their support. Graphical abstract was created and exported with BioRender.com under a paid subscription.

**Author Contributions**

Q.C.F., Z.W.S., F.X.W., C.W.W. and H.Z. designed the experiments. C.W.W., H.Z., L.M.W., Q.G., and H.L.L. collected and analyzed the data. H.Y., J.G., Y.H.K., X.P.Y., H.T.L., C.Q.L, F.Z. and Y.H.Z carried out mice assays. L.M.W., H.L.L. and Y.Q.D. carried out authentic virus assays. L.M.W., H.L.L., C.J.W, D.Y.L, H.PW, Y.M.P; L.X, J.L.L, X.M.Z., X.L.Y and Q.L.Y. carried out cell lines experiments. L.M.W., C.W.W. and H.Z. analyzed the data and prepared the manuscript.

**Competing Interests Statement**

The authors have declared that no competing interests exist.

**References**

1. Roder, P. V., Wu, B., Liu, Y. & Han, W. Pancreatic regulation of glucose homeostasis. *Exp Mol Med* **48**, e219, doi:10.1038/emm.2016.6 (2016).

2. Sharabi, K., Tavares, C. D., Rines, A. K. & Puigserver, P. Molecular pathophysiology of hepatic glucose production. *Mol Aspects Med* **46**, 21-33, doi:10.1016/j.mam.2015.09.003 (2015).

3. Chadt, A. & Al-Hasani, H. Glucose transporters in adipose tissue, liver, and skeletal muscle in metabolic health and disease. *Pflugers Arch* **472**, 1273-1298, doi:10.1007/s00424-020-02417-x (2020).

4. Kowalski, G. M. & Bruce, C. R. The regulation of glucose metabolism: implications and considerations for the assessment of glucose homeostasis in rodents. *Am J Physiol Endocrinol Metab*
5 Chung, S. T., Chacko, S. K., Sunehag, A. L. & Haymond, M. W. Measurements of Gluconeogenesis and Glycogenolysis: A Methodological Review. *Diabetes* **64**, 3996-4010, doi:10.2337/db15-0640 (2015).

6 Zhang, X., Yang, S., Chen, J. & Su, Z. Unraveling the Regulation of Hepatic Gluconeogenesis. *Front Endocrinol (Lausanne)* **9**, 802, doi:10.3389/fendo.2018.00802 (2018).

7 Fleig, W. E., Noether-Fleig, G., Roeben, H. & Ditschuneit, H. Hormonal regulation of key gluconeogenic enzymes and glucose release in cultured hepatocytes: effects of dexamethasone and gastrointestinal hormones on glucagon action. *Arch Biochem Biophys* **229**, 368-378, doi:10.1016/0003-9861(84)90164-4 (1984).

8 Deng, L. *et al.* Hepatitis C virus infection promotes hepatic gluconeogenesis through an NS5A-mediated, FoxO1-dependent pathway. *J Virol* **85**, 8556-8568, doi:10.1128/JVI.00146-11 (2011).

9 Petersen, M. C., Vatner, D. F. & Shulman, G. I. Regulation of hepatic glucose metabolism in health and disease. *Nat Rev Endocrinol* **13**, 572-587, doi:10.1038/nrendo.2017.80 (2017).

10 Cristelo, C., Azevedo, C., Marques, J. M., Nunes, R. & Sarmento, B. SARS-CoV-2 and diabetes: New challenges for the disease. *Diabetes Res Clin Pract* **164**, 108228, doi:10.1016/j.diabres.2020.108228 (2020).

11 Lim, S., Bae, J. H., Kwon, H. S. & Nauck, M. A. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. *Nat Rev Endocrinol* **17**, 11-30, doi:10.1038/s41574-020-00435-4 (2021).

12 Sathish, T. & Chandrika Anton, M. Newly diagnosed diabetes in patients with mild to moderate COVID-19. *Diabetes Metab Syndr* **15**, 569-571, doi:10.1016/j.dsx.2021.02.034 (2021).

13 Alves, A. M., Yvamoto, E. Y., Marzinotto, M. A. N., Teixeira, A. C. S. & Carrilho, F. J. SARS-CoV-2 leading to acute pancreatitis: an unusual presentation. *Braz J Infect Dis* **24**, 561-564, doi:10.1016/j.bjid.2020.08.011 (2020).

14 Liu, F. *et al.* ACE2 Expression in Pancreas May Cause Pancreatic Damage After SARS-CoV-2 Infection. *Clin Gastroenterol Hepatol* **18**, 2128-2130 e2122, doi:10.1016/j.cgh.2020.04.040 (2020).

15 Hu, L., Li, L., Xie, H., Gu, Y. & Peng, T. The Golgi localization of GOLPH2 (GP73/GOLM1) is determined by the transmembrane and cytoplasmic sequences. *PLoS One* **6**, e28207, doi:10.1371/journal.pone.0028207 (2011).

16 Puri, S., Bachert, C., Fimmel, C. J. & Linstedt, A. D. Cycling of early Golgi proteins via the cell surface and endosomes upon lumenal pH disruption. *Traffic* **3**, 641-653, doi:10.1034/j.1600-0854.2002.30906.x (2002).
17 Wei, C. et al. Tumor Microenvironment Regulation by the Endoplasmic Reticulum Stress Transmission Mediator Golgi Protein 73 in Mice. *Hepatology* **70**, 851-870, doi:10.1002/hep.30549 (2019).

18 Gatselis, N. K. et al. Golgi protein-73: A biomarker for assessing cirrhosis and prognosis of liver disease patients. *World J Gastroenterol* **26**, 5130-5145, doi:10.3748/wjg.v26.i34.5130 (2020).

19 Alqahtani, S. A. & Schattenberg, J. M. Liver injury in COVID-19: The current evidence. *United European Gastroenterol J* **8**, 509-519, doi:10.1177/2050640620924157 (2020).

20 Romere, C. et al. Asprosin, a Fasting-Induced Glucogenic Protein Hormone. *Cell* **165**, 566-579, doi:10.1016/j.cell.2016.02.063 (2016).

21 Yabaluri, N. & Bashyam, M. D. Hormonal regulation of gluconeogenic gene transcription in the liver. *J Biosci* **35**, 473-484, doi:10.1007/s12038-010-0052-0 (2010).

22 Yang, J. K., Lin, S. S., Ji, X. J. & Guo, L. M. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. *Acta Diabetol* **47**, 193-199, doi:10.1007/s00592-009-0109-4 (2010).

23 Wang, Y. & Wan, Y. Y. Golgi protein 73, hepatocellular carcinoma and other types of cancers. *Liver Res* **4**, 161-167, doi:10.1016/j.livres.2020.09.003 (2020).

24 Zhang, X. et al. GP73 represses host innate immune response to promote virus replication by facilitating MAVS and TRAF6 degradation. *PLoS Pathog* **13**, e1006321, doi:10.1371/journal.ppat.1006321 (2017).

**Tables**

Table 1. Clinical characteristics of COVID-19 patients and reference controls
| Parameter               | COVID-19 (n=136) | Reference (n=100) | P value |
|-------------------------|------------------|-------------------|---------|
| **Clinical characteristics** |                  |                   |         |
| Age (y)                 | 60 ± 14          | 58 ± 15           | 0.2939  |
| Male (n)                | 78               | 59                |         |
| Female (n)              | 58               | 41                |         |
| **Laboratory examination** |                  |                   |         |
| Leukocytes (10^9/L)     | 6.47 ± 5.15      | 5.13 ± 2.29       | 0.0158  |
| Lymphocytes (10^9/L)    | 1.56 ± 0.67      | 1.31 ± 0.45       | 0.0014  |
| Neutrophils (10^9/L)    | 4.09 ± 1.99      | 3.05 ± 1.56       | □0.0001 |
| Monocytes (10^9/L)      | 0.45 ± 0.15      | 0.41 ± 0.21       | 0.0891  |
| Platelets (10^9/L)      | 209.44 ± 66.69   | 215.56 ± 76.67    | 0.5140  |
| CRP (mg/L)              | 22.91 ± 11.98    | 5.41 ± 2.65       | □0.0001 |
| ALT (40 U/L)            | 34.96 ± 29.09    | 18.61 ± 9.58      | □0.0001 |
| AST (40 U/L)            | 26.88 ± 18.27    | 16.16 ± 4.80      | □0.0001 |
| BG (mmol/L)             | 102.27 ±32.97    | 88.21 ±7.73       | 0.0409  |

Abbreviations: CRP, C-reactive protein; ALT, alanine transaminase; AST, Aspartate transaminase; BG, blood glucose.
P value was calculated using the Mann-Whitney U test for continuous variables between two groups.

Table 2. Clinical characteristics of COVID-19 patients with disease severity
| Parameter          | Mild (n=50) | Moderate (n=65) | Severe (n=21) | P value |
|-------------------|-------------|----------------|--------------|---------|
| **Clinical characteristics** |             |                |              |         |
| Age (y)           | 54±13       | 61±12          | 65±10        | 0.0007  |
| Male (n)          | 27          | 36             | 16           |         |
| Female (n)        | 23          | 29             | 5            |         |
| **Laboratory examination** |           |                |              |         |
| Leukocytes (10⁹/L) | 4.55±2.09   | 6.77±2.02      | 8.63±3.08    | <0.0001 |
| Lymphocytes (10⁹/L)| 1.75±0.57   | 1.64±0.65      | 1.00±0.63    | <0.0001 |
| Neutrophils (10⁹/L)| 3.32±0.95   | 3.77±1.49      | 6.37±2.85    | <0.0001 |
| Monocytes (10⁹/L)   | 0.43±0.13   | 0.47±0.16      | 0.42±0.18    | 0.2580  |
| Platelets (10⁹/L) | 215.3±55.5  | 217.1±59.5     | 176.4±93.2   | 0.0361  |
| CRP (mg/L)        | 7.08±3.04   | 18.46±9.79     | 38.9±28.43   | <0.0001 |
| ALT (40 U/L)      | 28.08±17.2  | 38.89±34.1     | 34.5±27.32   | 0.1315  |
| AST (40 U/L)      | 22.00±9.10  | 27.1±16.67     | 34.2±29.56   | 0.0224  |
| BG (mmol/L)       | 90.0±21.18  | 101.2±29.8     | 134.5±44.0   | <0.0001 |

Abbreviations: CRP, C-reactive protein; ALT, alanine transaminase; AST, Aspartate transaminase; BG, blood glucose.
P value was calculated using Fisher’s exact test or χ² test for categorical variables.

Table 3. Clinical characteristics of diabetics and reference controls
| Parameter          | Healthy (n=100) | Diabetics (n=190) | P value |
|-------------------|----------------|-------------------|---------|
| **Clinical characteristics** | | | |
| Age (y) | 58 ± 15 | 62 ± 11 | 0.0102 |
| Male (n) | 59 | 102 |  |
| Female (n) | 41 | 88 |  |
| **Laboratory examination** | | | |
| Leukocytes (10^9/L) | 5.13 ± 2.29 | 7.82 ± 3.39 | 0.0001 |
| Lymphocytes (10^9/L) | 1.31 ± 0.45 | 1.74 ± 0.63 | 0.0001 |
| Neutrophils (10^9/L) | 3.05 ± 1.56 | 5.43 ± 3.40 | 0.0001 |
| Monocytes (10^9/L) | 0.41 ± 0.21 | 0.49 ± 0.24 | 0.0052 |
| Platelets (10^9/L) | 215.56 ± 76.67 | 230.88 ± 54.29 | 0.04959 |
| CRP (mg/L) | 5.41 ± 2.65 | 10.71 ± 8.72 | 0.0001 |
| ALT (40 U/L) | 18.61 ± 9.58 | 32.03 ± 13.39 | 0.0001 |
| AST (40 U/L) | 16.16 ± 4.80 | 26.41 ± 14.26 | 0.0001 |
| BG (mmol/L) | 88.21 ± 7.73 | 177.66 ± 63.00 | 0.0001 |

Abbreviations: CRP, C-reactive protein; ALT, alanine transaminase; AST, Aspartate transaminase; BG, blood glucose.
P values of differences between the two groups were calculated using the Mann-Whitney U test for continuous variables.

Table 4. List of PCR primers used
| Gene name | Sequence (5’-3’) |
|-----------|-----------------|
| *Pcx*    | CTGAAGTTCAAAACAGTTCGAGG (Mus) |
| *Pck1*   | CTGCATAACGGTCTGGACTTC (Mus) |
| *G6pc*   | CGACTCGCTATCTCCAAGTG (Mus) |
| *Fbp1*   | CACCglucagonATCAAGCCATCT (Mus) |
| *GP73*   | CTCGGCCCTGGTTCTAA (Mus) |
| *Gapdh*  | TGTTCCTCGTCCCGTGA (Mus) |
| *Pc*     | ATGGGGAGGAGGTGACG (Homo) |
| *Pck1*   | CAGAAATGCTCCTCAGC (Homo) |
| *G6pc*   | TGCCTGCAATTTTCCCT (Homo) |
| *Fbp1*   | ATGGAGGAGGGCAGGAA (Homo) |
| *GP73*   | CCCAGAGATCGTTTGATCC (Homo) |
| *Gapdh*  | CCTTCCGTGTCCCCACT (Homo) |

Figures
Figure 1

SARS-CoV-2 infection promotes GP73 production and secretion. a, Plasma GP73 levels in healthy controls and COVID-19 patients. b, Plasma GP73 levels in healthy controls and COVID-19 patients with different disease severities. c-d, SARS-CoV-2 genome copy number per µL using specific primers for N (c) or ORF1b (d) in the supernatants of Huh-7 cells infected with SARS-CoV-2 for the indicated times and MOI. e-f, Supernatant GP73 levels in Huh-7 cells infected with SARS-CoV-2 at the indicated MOIs for 24 h (e) or with SARS-CoV-2 (MOI 0.1) for the indicated times (f). g, Intracellular GP73 levels in Huh-7 cells infected with SARS-CoV-2 (CoV-2) at the indicated MOIs for 24 h. h-i, Supernatant GP73 levels in WT or GP73 KO-1 Huh-7 cells infected with SARS-CoV-2 (MOI 0.1) for the indicated times. Data in (a) were analyzed by Mann-Whitney U test; data in (b), (e) and (i) were analyzed by one-way ANOVA followed by Bonferroni’s post hoc test; data in (f) were analyzed by two-way ANOVA followed by Bonferroni’s post hoc test.
Figure 2

Increase in circulating GP73 elevates fasting blood glucose. a, Plasma glucose levels at the indicated times after a single dose of intravenous (i.v.) rmGP73 (0.1 mg/kg) or PBS in mice subjected to a preceding 12 h fast (n = 6). b, Plasma glucose levels 15 min after rmGP73 injection with IgG isotype or
anti-GP73 antibody (n = 5). c, Plasma insulin levels 15 min after rmGP73 injection (n = 6). d, Plasma glucose levels 24 h or 48 h after rmGP73 injection (n = 6). e, Plasma glucose levels at the indicated times after rmGP73 injection once daily for three days (n = 6). f-j, Insulin tolerance test (ITT; f), glucose tolerance test (GTT; g), pyruvate tolerance test (PTT; h), PTT with or without anti-GP73 antibody (i), or alanine tolerance test (ATT; j) in mice 24 h after rmGP73 injection (n=6). k, Glycogen levels 15 min after rmGP73 or PBS injection (n=3). l, Plasma glucose levels 15 min after injection of IgG isotype or anti-GP73 antibody in mice subjected to a preceding 12 h fast (n = 6). Data in (a), (e), (g), (h), (i) and (j) were analyzed by two-way ANOVA followed by Bonferroni’s post hoc test; data in (b) were analyzed by one-way ANOVA followed by Bonferroni’s post hoc test; data in (c), (d) and (l) were analyzed by two-tailed t-tests. The data are presented as the means ± SEMs. **P < 0.01; ***P < 0.001.
Figure 3

Circulating GP73 traffics to liver and kidney to stimulate gluconeogenesis. a, In vivo imaging of various organs from mice 30 min after rmGP73-Cy7 or free Cy7 injection. Two representative images are shown. b, The level of biotin on the hepatocyte surface upon incubation of HepG2 cells with increasing concentrations of rhGP73-biotin. Specific binding (shown in red) was calculated as the difference between the two curves. c, Glucose production in PMHs treated with rmGP73 at the indicated
concentrations for 2 h. d, Gluconeogenesis gene expression in PMHs treated with 32 nM rmGP73 for 2 h.
e-f, Immunoblotting analysis of phosphorylated PKA C subunit (PKA-C-α-p) levels and substrate
(phosphoRRXT*T*-PKA substrate, RRXpS/T) levels in HepG2 (e) or HK2 (f) cells treated with 32 nM
rmGP73 or IBMX for the indicated times. g, Immunoblotting analysis of phosphorylated AKT (AKT-p) in
PMHs, HepG2, or L6 cells treated with the indicated concentrations of insulin in the presence or absence
of GP73. Data in (c) were analyzed by one-way ANOVA followed by Bonferroni’s post hoc test; data in (d)
were analyzed by two-tailed t-tests. Cell-based studies were performed independently at least three times
with comparable results. The data are presented as the means ± SEMs. **P < 0.01; ***P < 0.001.
Figure 4

GP73 induces a drastic remodeling of the PKA kinase hub. a, Overlapping numbers of significantly upregulated phosphopeptides and downregulated phosphopeptides in PMHs treated with rmGP73 (64 nM) or glucagon (3 μM) for 1 h. Localization probability ≥0.75 and fold-change ≥1.5 or fold-change ≤0.67 were declared significant. Significantly regulated phosphopeptides by GP73 are shown in blue, by glucagon are shown in red. b, Heatmap of the top 30 highly upregulated phosphosites in PMHs treated...
with rmGP73. c, Network analysis of proteins involved in the glucogenesis signaling pathway in PMHs treated with rmGP73. Each of the phosphosites are color-coded based on the fold changes. Circular shapes show each protein that is upregulated in GP73-treated cells compared to PBS-treated cells. Lines indicate protein-protein interactions curated from databases of experimentally defined kinase-substrate relationships (STRING, confidence >0.7). d-e, Specific kinase substrate motifs (d) or distribution of matching kinases (e) according to the phosphoproteomics data from the rmGP73-treated sample (P <0.05) using MoMo (http://meme-suite.org/tools/momo) and Kinase Enrichment Analysis 2 (KEA2). f, KEGG enriched pathway analysis of significantly regulated phosphopeptides in PMHs treated with rmGP73 (P <0.05) using DAVID Bioinformatics Resources 6.8. The bar plot shows significantly dysregulated pathways, and Fisher's exact test P values are shown on the x-axis.
Figure 5

GP73 is secreted from multiple tissues upon fasting and under glucotoxic conditions. a, Plasma GP73 levels in humans following an overnight fast (n=7). b, Plasma GP73 levels in mice fed ad libitum (ad-lib) or fasted for 24 h (n=6). c, GP73 mRNA expression in the livers or kidneys of mice fasted for the indicated times (n=3). d, Representative confocal immunofluorescence images of GP73 staining in liver and WAT sections from mice fed ad libitum or fasted for 24 h. Green represents GP73, and blue represents the
nucleus. e, Correlation analysis between plasma GP73 levels and glucose levels in COVID-19 patients. f, Plasma GP73 levels in healthy and diabetic patients. g, Correlation analysis between plasma GP73 levels and HbA1c levels in diabetic patients. h-i, GP73 mRNA expression in various mouse organs from mice 30 min after i.v. injection of PBS or high glucose (n=3; h) or 8 week after fed with regular diet (chow) or high fat diet (HFD) along with STZ injection (n=3;i). Data in (a), (h) and (i) were analyzed by two-tailed t-tests; data in (b) and (c) were analyzed by one-way ANOVA followed by Bonferroni’s post hoc test; data in (e) and (g) were analyzed were analyzed by Spearman’s non-parametric test; data in (f) were analyzed by Mann-Whitney U test. Cell-based studies were performed independently at least three times with comparable results. The data are presented as the means ± SEMs. *P < 0.05; **P < 0.01; ***P < 0.001.
GP73 blockade reduces excessive gluconeogenesis associated with SARS-CoV-2 infection and diabetes. 

a-b, Glucogenic gene expression (a) or glucose levels (b) in Huh-7 cells infected with SARS-CoV-2 (MOI 0.1) for 24 h with or without GP73 antibody (1 µg/mL). 

c, Glucose levels in WT and GP73 KO-1 Huh-7 cells infected with SARS-CoV-2 (MOI 0.1) for 24 h in glucose-free medium. 

d, Immunoblotting analysis of PKA-C-α phosphorylation and substrate levels in Huh-7 cells treated with SARS-CoV-2 or the indicated
serum. e, Glucogenic gene expression in Huh-7 cells cultured with the indicated serum with or without GP73 antibody. f, Fasting glucose levels in BKS and db/db mice (n=6). g-h, Fasting glucose levels in db/db mice (g) or HFD+STZ-induced T2D mice (h) at the indicated times after anti-GP73 treatment (n=6). Data in (a), (b), (c) and (e) were analyzed by one-way ANOVA followed by Bonferroni’s post hoc test; data in (f), (g) and (h) were analyzed by two-tailed t-tests. Cell-based studies were performed independently at least three times with comparable results. The data are presented as the means ± SEMs. *P < 0.05; **P < 0.01; ***P < 0.001.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- ExtendedDataFigure1.jpg
- ExtendedDataFigure2.jpg
- ExtendedDataFigure3.jpg
- ExtendedDataFigure4.jpg
- ExtendedDataFigure5.jpg
- ExtendedDataFigure6.jpg
- ExtendedDataFigure7.jpg
- ExtendedDataFigure8.jpg
- ExtendedDataFigure9.jpg
- ExtendedDataFigure10.jpg